Abstract
Antibodies play a central role in humoral immunity and have been developed not only as reagents for the detection and diagnosis but also as clinical products due to its high affinity and specificity. Approximately 20 therapeutic antibodies have been approved by the FDA, and there are more than 100 additional antibodies in clinical development. In the development of antibody drugs, problems such as limited efficacy and high production costs have become so serious that attempts are now being made to construct highly effective and potent recombinant antibodies from human and/or humanized protein fragments. In this review, we focused on bispecific antibodies retargeting of lymphocytes against tumor cells and introduced its perspective as a novel reagent for cancer therapy.
